Karsten Lollike is the Corporate Vice President and the Qualified Person Responsible for Pharmacovigilance (QPPV) of Global Safety at Novo Nordisk, a position he has held for 11 years. Dr. Lollike joined Novo Nordisk in 2000, working in Global Development in Haemostasis, after obtaining his medical degree and subsequently a PhD. We spoke to Dr. Lollike about his medical expertise and experience, his long-standing career at Novo Nordisk, and what working at the company means to him.

IMMUNE rejection is one of the most serious risks of organ transplantation, an increasingly common procedure that is granting patients across the world…

Calcium signalling is essential for inter and intra-cellular neuronal communication, and efforts for improving its imaging are constantly ongoing…

UNDERSTANDABLE optimism surrounds nanoparticle technology and its application for the treatment of diseases such as cancer…

NephMadness, now in its 7th year, is a derivative of the annual USA collegiate basketball championships, colloquially known as March Madness.

Affecting up to 11.4% of the population worldwide, psoriasis is one of the most common chronic autoinflammatory diseases.

This review starts with an excellent description of the pathophysiology of bronchopulmonary dysplasia, which should be informative to physicians who will…

Food hypersensitivity (FH), which includes food allergy and intolerance, is an adverse reaction to food causing unpleasant…

Chronic urticaria is one of the most commonly diagnosed dermatoses. Following diagnosis, correct identification and proper treatment significantly reduces disease activity, thereby improving the patient’s quality of life.